MedTrace Logo

Expanded Access to Zofin for Patients With COVID-19

NCT04657406 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2023-03-23

No results posted yet for this study

Summary

This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider to be at high risk of progression to moderate disease.

Conditions

  • Covid19
  • Corona Virus Infection
  • SARS (Severe Acute Respiratory Syndrome)
  • Acute Respiratory Distress Syndrome

Interventions

DRUG

Zofin

Subjects will receive standard of care plus 1 mL of Zofin on day 0, day 4 and day 8, containing 1-5 x 10\^11 particles/mL.

Sponsors & Collaborators

  • ZEO ScientifiX, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04657406 on ClinicalTrials.gov